The University of Kansas Health System Center for Concussion Management will hold its 4th Annual Symposium on August 6, 2022.

Written By Lindsey McClelland

The University of Kansas Health System Center for Concussion Management will hold its 4th Annual Symposium on August 6, 2022. Dr. Michael Rippee, MD, Associate Professor of Neurology, Sports Neurologist and Medical Director of the Center for Concussion Management at The University of Kansas Health System will speak about The Future of Treatment: What is on the Horizon? Dr. Rippee is the Primary Investigator of the Phase 2 Trial of Oxeia Biopharmaceuticals’ drug, OXE103, for the treatment of concussion. Learn more about the Symposium and the full roster of speakers and presentations at:

https://www.eeds.com/portal_live_events.aspx?ConferenceID=415377

Lindsey McClelland
Previous

OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS
Next

Dr. Rippee speaks about enrolling patients in Oxeia’s Phase 2 Clinical Trial for Concussions on KU’s Morning Medical Update